ECSP034450A - Nueva composicion farmaceutica - Google Patents

Nueva composicion farmaceutica

Info

Publication number
ECSP034450A
ECSP034450A EC2003004450A ECSP034450A ECSP034450A EC SP034450 A ECSP034450 A EC SP034450A EC 2003004450 A EC2003004450 A EC 2003004450A EC SP034450 A ECSP034450 A EC SP034450A EC SP034450 A ECSP034450 A EC SP034450A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
new pharmaceutical
relates
present
composition
Prior art date
Application number
EC2003004450A
Other languages
English (en)
Inventor
Paul Hadvary
Pierre Barbier
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034450A publication Critical patent/ECSP034450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a combinaciones, composiciones y procedimientos farmacéuticos, para el tratamiento de la obesidad. De una forma más particular la presente invención se refiere a una combinación o composición que comprende orlistat, y un secuestrante de ácidos biliares.
EC2003004450A 2000-07-28 2003-01-24 Nueva composicion farmaceutica ECSP034450A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28

Publications (1)

Publication Number Publication Date
ECSP034450A true ECSP034450A (es) 2003-03-10

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004450A ECSP034450A (es) 2000-07-28 2003-01-24 Nueva composicion farmaceutica

Country Status (38)

Country Link
US (5) US6756364B2 (es)
EP (1) EP1307264B1 (es)
JP (2) JP4265911B2 (es)
KR (1) KR100572785B1 (es)
CN (1) CN100423715C (es)
AR (1) AR033548A1 (es)
AT (1) ATE279961T1 (es)
AU (2) AU8969901A (es)
BR (1) BR0112799B1 (es)
CA (1) CA2416901C (es)
CZ (1) CZ302087B6 (es)
DE (1) DE60106623T2 (es)
EC (1) ECSP034450A (es)
EG (1) EG24357A (es)
ES (1) ES2230362T3 (es)
GT (1) GT200100152A (es)
HK (1) HK1058636A1 (es)
HR (1) HRP20030029B1 (es)
HU (1) HU229292B1 (es)
IL (2) IL154008A0 (es)
JO (1) JO2320B1 (es)
MA (1) MA26937A1 (es)
ME (1) MEP90508A (es)
MX (1) MXPA03000771A (es)
MY (1) MY127247A (es)
NO (1) NO330546B1 (es)
NZ (1) NZ523684A (es)
PA (1) PA8523201A1 (es)
PE (1) PE20020336A1 (es)
PL (1) PL204443B1 (es)
PT (1) PT1307264E (es)
RS (1) RS50397B (es)
RU (1) RU2241462C2 (es)
SI (1) SI1307264T1 (es)
TW (1) TWI275395B (es)
UY (1) UY26860A1 (es)
WO (1) WO2002009815A2 (es)
ZA (1) ZA200300456B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416900C (en) * 2000-07-28 2007-07-03 F. Hoffmann-La Roche Ag The use of a combination of a lipase inhibitor and a pharmaceutically acceptable bile acid sequestrant for the prevention and treatment of diseases associated with high plasma cholesterol levels
RS50397B (sr) * 2000-07-28 2009-12-31 F. Hoffmann-La Roche Ag., Farmaceutska smeša
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
ATE453390T1 (de) * 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
DE60304723T2 (de) * 2002-09-09 2007-04-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno VERZWEIGTE ALPHA-GLUCANE FüR DAS GEWICHTSMANAGEMENT
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US7648625B2 (en) * 2003-12-19 2010-01-19 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
EP1713402B1 (en) 2004-02-13 2018-07-04 Ethicon Endo-Surgery, Inc. Device for reducing stomach volume
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
US7708684B2 (en) 2004-02-27 2010-05-04 Satiety, Inc. Methods and devices for reducing hollow organ volume
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
WO2005097012A2 (en) 2004-03-26 2005-10-20 Satiety, Inc. Systems and methods for treating obesity
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
CA2610922A1 (en) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
CA2626734A1 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
NZ569756A (en) * 2005-12-12 2011-07-29 Allaccem Inc Methods and systems for preparing antimicrobial films and coatings utilising polycyclic bridged ammonium salts
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
WO2007086054A2 (en) * 2006-01-25 2007-08-02 Yeda Research And Development Co. Ltd. A process for preparing allylmercaptocaptopril (cpssa) and related asymmetrical disulfides
US7749536B2 (en) * 2006-02-14 2010-07-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
PT1818048E (pt) * 2006-02-14 2009-03-11 Teva Pharma Formulações farmacêuticas de polímeros aminados alifáticos e processos para a sua produção
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2661987C (en) 2006-09-01 2012-11-06 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) * 2006-10-24 2008-06-12 Thompson Md Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
CA2673665C (en) * 2006-12-22 2017-03-21 Ironwood Pharmaceuticals, Inc. Method and compositions for treating esophageal disorders
EP1944025A1 (en) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of orlistat
ES2522908T3 (es) 2007-02-21 2014-11-19 Allaccem, Inc. Composiciones a base de compuestos policíclicos con puente para la inhibición y el alivio de enfermedades
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
MX2009010552A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Antagonistas de receptor de opioide periferico y usos de los mismos.
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
RU2011112694A (ru) * 2008-09-02 2012-10-10 Юсв Лимитед (In) Сшитые полимеры
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
US20110152204A1 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
SG190029A1 (en) 2010-11-08 2013-06-28 Albireo Ab Ibat inhibitors for the treatment of liver diseases
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP2591768B1 (en) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
PL2916852T3 (pl) 2012-11-06 2021-11-02 Sigrid Therapeutics Ab Porowaty materiał z krzemionki do stosowania jako farmaceutyczny lub dietetyczny składnik czynny
TWI614017B (zh) 2012-12-21 2018-02-11 財團法人國家衛生研究院 包含中孔洞矽奈米粒子之組成物的用途
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3413875B1 (en) * 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
ATE277613T1 (de) 1995-12-26 2004-10-15 Suntory Ltd Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
IL137096A (en) 1998-01-09 2006-10-31 Genzyme Corp Pharmaceutical preparations or kits of parts containing lipid-binding polymers and lipase inhibitors and their use in the preparation of drugs for the treatment of obesity or hypertriglyceridemia
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
CN1170534C (zh) * 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
TR200100472T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
WO2000013667A1 (en) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP2002535288A (ja) 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ．ア．エッセ． リポタンパク質複合体およびそれらを含む組成物
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
RS50397B (sr) * 2000-07-28 2009-12-31 F. Hoffmann-La Roche Ag., Farmaceutska smeša

Also Published As

Publication number Publication date
IL154008A (en) 2011-12-29
HU229292B1 (en) 2013-10-28
TWI275395B (en) 2007-03-11
BR0112799A (pt) 2003-07-01
BR0112799B1 (pt) 2017-10-24
JO2320B1 (en) 2005-09-12
NO20030418L (no) 2003-01-27
CA2416901A1 (en) 2002-02-07
US20020035089A1 (en) 2002-03-21
CN1444495A (zh) 2003-09-24
EP1307264B1 (en) 2004-10-20
JP2004505067A (ja) 2004-02-19
JP2009073833A (ja) 2009-04-09
CZ2003582A3 (cs) 2004-02-18
SI1307264T1 (en) 2005-02-28
WO2002009815A2 (en) 2002-02-07
HRP20030029B1 (en) 2005-06-30
AR033548A1 (es) 2003-12-26
ME00671B (me) 2011-12-20
PL204443B1 (pl) 2010-01-29
EP1307264A2 (en) 2003-05-07
HUP0301281A2 (hu) 2003-08-28
CZ302087B6 (cs) 2010-10-06
CN100423715C (zh) 2008-10-08
DE60106623D1 (de) 2004-11-25
UY26860A1 (es) 2002-01-31
NZ523684A (en) 2005-04-29
US20040105838A1 (en) 2004-06-03
GT200100152A (es) 2002-05-16
KR20030029796A (ko) 2003-04-16
KR100572785B1 (ko) 2006-04-19
PE20020336A1 (es) 2002-05-08
US6756364B2 (en) 2004-06-29
PA8523201A1 (es) 2002-10-24
NO20030418D0 (no) 2003-01-27
HUP0301281A3 (en) 2005-05-30
MXPA03000771A (es) 2003-06-04
HRP20030029A2 (en) 2004-02-29
PL366105A1 (en) 2005-01-24
AU8969901A (en) 2002-02-13
US20050136030A1 (en) 2005-06-23
US8071571B2 (en) 2011-12-06
MA26937A1 (fr) 2004-12-20
US20060269510A1 (en) 2006-11-30
AU2001289699B2 (en) 2006-06-01
MEP90508A (en) 2011-12-20
IL154008A0 (en) 2003-07-31
ES2230362T3 (es) 2005-05-01
HK1058636A1 (en) 2004-05-28
ATE279961T1 (de) 2004-11-15
DE60106623T2 (de) 2006-02-02
NO330546B1 (no) 2011-05-16
JP4265911B2 (ja) 2009-05-20
RU2241462C2 (ru) 2004-12-10
US20100203032A1 (en) 2010-08-12
MY127247A (en) 2006-11-30
PT1307264E (pt) 2005-02-28
RS50397B (sr) 2009-12-31
EG24357A (en) 2009-03-04
YU5003A (sh) 2006-01-16
WO2002009815A3 (en) 2002-04-18
CA2416901C (en) 2007-07-03
ZA200300456B (en) 2004-04-16

Similar Documents

Publication Publication Date Title
ECSP034450A (es) Nueva composicion farmaceutica
ECSP045429A (es) Combinacion de compuestos organicos
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CR10680A (es) Composiciones de inhibidores de chk1
AR050717A1 (es) Composiciones farmaceuticas
PA8583501A1 (es) Derivados de pirrolidona como inhibidores de maob
AR109263A2 (es) Composición que comprende moxidectina
CR8341A (es) Una composicion y metodo de tratamiento para condiciones urogenitales
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
DE602004005890D1 (de) Moschus-geruchsstoffe
PA8571901A1 (es) Nueva composicion farmaceutica
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
UY27328A1 (es) Microcápsulas para la protección frente al mal aliento
BR0111785A (pt) Composições e métodos para tratamento de candidìase
UY27785A1 (es) Nueva composición farmacéutica
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
DK1144348T3 (da) LTA4-hydrolaseinhibitorer
ATE390144T1 (de) Behandlung von fibrosen